A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bronchial Asthma
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Catriona McMahon, MD, Principal Investigator, Affiliation: AZ UK MC
Tomas Andersson, MD, Study Director, Affiliation: AZ R&D Lund
Overall contact:
AstraZeneca Clinical Study, Information, Phone: 1-800-236-9933, Email: information.center@astrazeneca.com
Summary
To investigate how common it is that patients using Symibort SMART take high average daily
doses that are not considered appropriate by their physician (overuse) or are hospitalised
due to their asthma at least partly due to underuse.
Clinical Details
Official title: A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symibort SMART) Capturing Over Use and Under Use Via the General Practice Research Database
Study design: Prospective
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asthma diagnosis, patient registered with the prescribing physician for at least one
year before the qualifying prescription of Symbicort, prescription of Symbicort SMART
after UK launch of the concept
Exclusion Criteria:
- None
Locations and Contacts
AstraZeneca Clinical Study, Information, Phone: 1-800-236-9933, Email: information.center@astrazeneca.com
Research Site, London, United Kingdom; Recruiting
Additional Information
Starting date: July 2007
Last updated: January 9, 2008
|
